Is NMDA receptor hypofunction in schizophrenia associated with a primary hyperglutamatergic state?
Shim
Sung S
SS
Adityanjee
D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D018698:Glutamic Acid / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007649:Ketamine / Q000494:pharmacology; D000077213:Lamotrigine; D008954:Models, Biological; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D017966:Pyramidal Cells / Q000187:drug effects / Q000502:physiology; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000502:physiology*; D012559:Schizophrenia / Q000175:diagnosis / Q000503:physiopathology*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D014227:Triazines / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000187:drug effects / Q000502:physiology*
D018691:Excitatory Amino Acid Antagonists; D016194:Receptors, N-Methyl-D-Aspartate; D014227:Triazines; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; D007649:Ketamine; D000077213:Lamotrigine